Autopsy report · NCT04931849

Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma (APATIT-G)

“PI and Sponsor decided to not proceed with the trial.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Early Phase 1

Sponsor

University of Rochester

Sponsor type

University, hospital or other

Conditions

Thrombocytopenia

Interventions

Avatrombopag

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
  “The sponsor decided not to conduct the expansion part of trial (part 2)” (80% match in meaning)
• CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
  “Sponsor decision to not initiate the trial” (78% match in meaning)
• A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
  “Sponsor decision not to start trial” (78% match in meaning)
• Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
  “The PI left the Institution and sponsor decided to close the trial.” (78% match in meaning)
• Pancreatic Enzyme Supplementation for Celiac Disease
  “The trial was terminated prematurely by the sponsor for administrative reasons.” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.